Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 27;71(7):1426–1439. doi: 10.1136/gutjnl-2021-326784

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Impact of IBD treatments on COVID-19 outcomes. Relative risks were calculated using multivariable logistic regression models comparing outcomes of COVID-19 from each medication class to those not treated with that medication. ICU admission encompassed composite outcomes made up by ICU admission, mechanical ventilation and mortality not due to COVID-19. The colours on the indicator represent the collective risk of IBD medications on COVID-19 outcomes: green=low risk, amber=moderate risk, red=high risk. *Indicates significant results where the 95% CI did not cross 1. Figure created with data from refs. ^{30 36} and using BioRender.com. 5-ASA, 5-aminosalicylic acid; IBD, inflammatory bowel disease; ICU, intensive care unit; JAK-inhibitor, Janus kinase inhibitor; RR, relative risk; TNF, tumour necrosis factor.